Cannabis News Box

Curaleaf removes CBD health claims from website and social media after FDA warning

Curaleaf removes CBD health claims from website and social media after FDA warning

Bethan Rose Jenkins, Cannabis News Writer/Editorial

August 7, 2019

At the end of last month, leading medical and wellness cannabis operator Curaleaf Holdings Inc. was given a warning by the Food and Drug Administration (FDA) for making false health claims about the CBD-containing products for sale on its website. Curaleaf serves over 150,000 registered medical canna...

Cannabis-based epilepsy treatment Epidiolex will cost $32,500 annually

Cannabis-based epilepsy treatment Epidiolex will cost $32,500 annually

Bethan Rose Jenkins, Cannabis News Writer/Editorial

August 29, 2018

Epilepsy sufferers may never have to worry about enduring bouts of life-threatening seizures ever again, thanks to the Food and Drug Administration (FDA) approving the world’s first ever cannabis-derived medication for the treatment of two rare types of pediatric epilepsy. The discussion surrounding ...

CEO of GW Pharma talks about Epidiolex getting FDA approval

CEO of GW Pharma talks about Epidiolex getting FDA approval

Bethan Rose Jenkins, Cannabis News Writer/Editorial

July 2, 2018

On Monday, Justin Gover hit a milestone in his career. He is the CEO of GW Pharmaceuticals – a company that created a cannabis-based medicine called Epidiolex. Not only is Epidiolex being used to treat two forms of epilepsy but also, it is non-psychoactive, what with it containing the cannabis com...

Rescheduling cannabis in the States: Could the decision backfire?

Rescheduling cannabis in the States: Could the decision backfire?

Bethan Rose Jenkins, Cannabis News Writer/Editorial

June 17, 2018

Cannabis is listed as a Schedule I narcotic, but things could be about to change. If the plant is moved to Schedule II, medical patients everywhere will rejoice. But what if the decision to reschedule cannabis in the United States backfires? There's a chance it might. If the Food and Drug Adminis...

Will Epidiolex be the first cannabis-based drug to be approved as an epilepsy treatment?

Will Epidiolex be the first cannabis-based drug to be approved as an epilepsy treatment?

Bethan Rose Jenkins, Cannabis News Writer/Editorial

May 3, 2018

A cannabis-based medication for epilepsy could be the first to gain approval by the Food and Drug Administration (FDA). Created by British company GW Pharmaceuticals, cannabis-based epilepsy treatment Epidiolex will undergo FDA review this June. Things are looking hopeful, with a panel of 13 advisors...

FDA gives positive review for GW Pharmaceuticals’ cannabis-based medicine Epidiolex

FDA gives positive review for GW Pharmaceuticals’ cannabis-based medicine Epidiolex

Bethan Rose Jenkins, Cannabis News Writer/Editorial

April 19, 2018

Epidiolex, a cannabis-based treatment for epilepsy from GW Pharmaceuticals, received a positive review from staff at the Federal Drug Administration (FDA) on Tuesday. GW Pharmaceuticals provided “substantial evidence” to prove the drug’s suitability for treating two rare types of epilepsy. ...

WHO declares CBD as safe for human consumption

WHO declares CBD as safe for human consumption

February 22, 2018

The World Health Organization (WHO) released a report stating CBD oil is a safe and effective medicine. The report affirms the medicine's effectiveness while adding there are no known side effects or potential for abuse. “To date, there is no evidence of the recreational use of CBD or any public health-rela...

U.S. Surgeon General supports studying medical cannabis, but opposes social use

U.S. Surgeon General supports studying medical cannabis, but opposes social use

Sara Tiradossi

December 6, 2017

U.S. Surgeon General Jerome Adams said he supports medical cannabis research, but still opposes social use legalization. According to Adams, who spoke at the National Black Caucus of State Legislators’ annual conference in Indianapolis, medical cannabis “should be like any other drug.” “We...

New study: nearly 70 percent of CBD extracts labeled incorrectly

New study: nearly 70 percent of CBD extracts labeled incorrectly

Sara Tiradossi

November 10, 2017

Medical cannabis is legal in more than half of U.S. states, but it still remains illegal under federal law. The Food and Drug Administration does not in fact regulate derivatives of the plant, such as CBD extracts. CBD is one of the active ingredients in cannabis that is widely thought to offer a...

FDA commissioner threatens legal action against medical cannabis companies’ medical claims

FDA commissioner threatens legal action against medical cannabis companies’ medical claims

Logan Lowrey-Rasmussen

October 4, 2017

On Tuesday, Food and Drug Administration (FDA) Commissioner Scott Gottlieb said the agency could begin prosecuting cannabis companies who claim unproven health benefits in their products.  The FDA commissioner said entities are developing products and making claims which tout the anti-tumor effec...

A new bill could completely change cannabis research

A new bill could completely change cannabis research

September 20, 2017

Thor Benson / Cannabis News Box Contributor If anyone knows how hard it is to study the medicinal benefits of cannabis, it’s Dr. Sue Sisley. Sisley is a physician who has worked with veterans for over 20 years and has been studying how cannabis could help treat Post-Traumatic Stress Disorder (PTSD). Sisley has dealt with burdensome regulations, a DEA a...

Sessions further impedes cannabis research

Sessions further impedes cannabis research

Logan Lowrey-Rasmussen

August 21, 2017

An anonymous senior Drug Enforcement Agency (DEA) official claimed Attorney General Jeff Sessions had effectively blocked an Obama Administration initiative to expand the number of cannabis suppliers for scientific research. Sessions or the Department of Justice had not released an official statement, but did not respond or take action on two dozen requests to grow cannabis for research. The Controlled Substances Act lists cannabis as a Schedule I drug, classifying it as more dangerous than cocaine. The Schedule I status of cannabis means the government does not recognize any legitimate medical use for the plant, which makes attaining the plant for research more difficult. Cannabis researchers who wish to conduct federal studies need a license from the DEA, approval from the U.S. Food and Drug Administration (FDA) and access to the single authorized source of legal cannabis from the University of Mississippi. Researchers had often complained about the low quality of cannabis the university produced. Late in the Obama administration, the DEA relaxed the constraints on cannabis production for research purposes and allowed other groups to apply for authorization to grow. In early August, the DEA released productio...

FDA